Cyclo Therapeutics’ Trappsol Cyclo was able to induce clinical improvement in seven out of eight children with Neimann-Pick ...

The biotechnology sector is filled with high-potential growth stocks. With advancements in artificial intelligence (AI), biotech remains at the cutting edge of medical and scientific innovation, ...

In the space of four days, the number of FDA-approved therapies for ultra-rare genetic disorder Niemann-Pick disease has gone from zero to two, transforming the prospects for patients. IntraBio's ...

evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1). The findings were presented at the 21st Annual WORLDSymposium™ in San Diego, California. According to ...

GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (NASDAQ:CYTH), a clinical-stage biotechnology firm with a market capitalization of $22.15 million, announced positive data from a sub-study of its pivotal ...

What is Niemann-Pick disease type C? Niemann-Pick disease type C is a rare neurodegenerative disorder caused by cholesterol transport issues, leading to severe neurological impairments.

Niemann-Pick disease type C (NPC) is an ultra-rare, progressive, and neurodegenerative lysosomal storage disorder characterized by an inability of the body to transport cholesterol and other ...

Accumulation of fat molecules is detrimental to the cell. Researchers from the Yong Loo Lin School of Medicine, National ...

Accumulation of fat molecules is detrimental to the cell. Researchers have made a breakthrough in understanding how our cells manage to stay healthy by recycling important fat molecules. Their study ...

The protein Spns1 helps transport fat molecules out of lysosomes, preventing harmful buildup and offering insights for rare ...

Accumulation of fat molecules is detrimental to the cell. Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have made a breakthrough in ...